


Backgrounder: SLActive

SLActive – the third generation in implant surface technology



The molecular surface structure of SLActive

A new dental implant surface technology, which has proven to cut healing times in half to just 3-4 weeks¹, was launched in Europe, North America and initial markets in Asia in 2006. Marketed under the trade name 'SLActive', the new technology has been pioneered by Straumann, a global leader in implant dentistry and dental tissue regeneration, and is available on a broad range of the company's implant types.

An extensive ongoing international clinical trial in 19 centers has shown that SLActive generally achieves excellent results even when the implant is loaded immediately or sooner after placement than usual. In addition to this benefit of shorter treatment protocols, SLActive could open the door to successful implant treatment in patients with poor bone quality or other challenging treatment situations such as patients with diabetes, osteoporosis, or patients who smoke.

The enhanced surface properties, activated tissue responses and rapid osseointegration with SLActive make it – in the words of Professor Axel Zöllner, University of Witten/Herdecke, Germany “an evolutionary step towards a revolution in dentistry”. It thus promises to set a new standard in tooth replacement and patient care and is supported by more scientific studies than any other dental implant technology at market launch because it is based and builds on the scientific data supporting the renowned and well documented SLA surface.

These attributes won SLActive the 2005 Medical Device Technology of the Year Award in a poll of independent experts conducted by business consultants Frost and Sullivan.

Healing times halved to 3-4 weeks

When Straumann developed the forerunner of SLActive - the SLA surface - in 1994, it dramatically reduced healing times from 12 to 6 weeks. SLA consequently became the gold standard in implant dentistry and has hitherto remained the scientifically proven benchmark. SLA received FDA clearance for immediate loading back in 1999*.

With SLActive, the next generation implant technology, Straumann has again cut healing times by half, bringing them down to 3 to 4 weeks. The implications of this are: shorter treatment protocols, higher predictability and increased confidence with earlier loading, resulting in better patient care. Like SLA, SLActive offers the options of immediate loading* and immediate function.

Preclinical evidence for greater and faster implant stability

SLActive uses the same initial manufacturing process as SLA, involving Sandblasting with Large grit followed by Acid etching to achieve an optimal topography for bone cells to attach themselves. SLActive is conditioned in nitrogen and immediately preserved in an isotonic saline solution. This maintains its high surface activity, which would otherwise be lost due to reaction with the atmosphere.

The importance of hydrophilicity

Conventional titanium surfaces are hydrophobic and thus repel fluids, whereas the chemical purity and retained surface energy of SLActive give it remarkable hydrophilic properties. This was demonstrated in four preclinical studies conducted at an early stage in development.^{2,3,4,5} As a consequence, the surface quickly attracts blood and proteins, promoting faster osseointegration around the implant.

Further preclinical results demonstrate increased bone-to-implant contact with the SLActive surface compared to the SLA surface at early healing periods of 2-4 weeks.⁶ This in turn results in earlier secondary implant stability in the critical early stage of healing.⁷

Three *in vitro* studies then demonstrated that early cell response to SLActive was enhanced by up to 15 fold.^{4,8,9} At the same time, other preclinical studies demonstrated that SLActive achieved up to 60% more bone at 2 weeks after placement by comparison with Straumann's gold-standard SLA surface.^{6,7,10}

Implants most at risk 2-4 weeks after placement

When dental implants are placed in the jawbone, their helical thread and rough surface provide them with a mechanical or 'primary' stability. However, as part of the body's bone-repair mechanism, the bone around the implant is initially resorbed and the primary stability of the implant erodes. New replacement bone is formed that integrates with the implant and gives it long-term secondary stability but there is a critical period when the latter process is not far enough advanced to compensate for the lost primary stability. This period, between 2 and 4 weeks after placement, is called the "stability dip"¹¹ and is the point at which the implant is at greatest risk to failure.

* With good primary stability and appropriate occlusal loading. Multiple tooth applications may be rigidly splinted. In edentulous cases, four or more implants must be used in immediate load cases.

By reducing healing times by half to just 3 - 4 weeks SLActive effectively minimizes the stability dip and increases implant stability, especially in the critical early stage of healing⁹. The implications of this are shorter treatment protocols, higher predictability and reduced risk with earlier loading, resulting in better patient care and satisfaction.




Fig. 2

Preclinical trial update

Current clinical results build on and confirm preclinical observations. At the *IDS 2007* in Cologne, Gilbert Achermann, President and CEO of Straumann, briefly discussed some of the impressive histological results observed in preclinical investigations, which were recently accepted for publication in a peer-reviewed journal.

A pilot preclinical study conducted by Dr Frank Schwarz *et al* demonstrated the accelerated healing processes around SLActive implants¹⁰. At day 1, stable blood clots were observed, compared with partially collapsed clots around SLA implants. Bone formation was more rapid with SLActive; highly mineralized, organized bone was observed around SLActive implants in comparison to unstructured bone around SLA implants. Significantly increased proliferation of vascular structures and osteocalcin formation was also observed with SLActive. A second study, recently published in the *Journal of Clinical Periodontology*, demonstrated the promotion of bone regeneration around SLActive implants in dehiscence defects, with significantly greater and more mature bone than around SLA implants. After 12 weeks, the defect around SLActive was completely filled with new bone, while new bone formation around SLA implants was limited to only the most apical part of the defect. New bone height, percent linear fill, bone-to-implant contact and area of new bone fill were significantly increased around SLActive implants compared to around SLA implants.¹²

In another ongoing preclinical study, osteoblastic activity, and therefore bone production, was observed around SLActive implants at 1 week. After just 2 weeks, bone formation and production were much more advanced around SLActive than SLA. The effects of SLActive on soft tissue attachment have also been investigated, showing enhanced epithelial cell and fibroblast attachment and proliferation, leading to soft tissue attachment with well organized collagen fibers and blood vessels.¹³

Clinical trials

Randomized, controlled, clinical trial shows earlier secondary implant stability during critical loading period

A dual-center, prospective, randomized, controlled, clinical trial performed in patients by a team led by Professor David Cochran has evaluated the comparative stability of SLActive and SLA in patients over the first 6 weeks of healing. Cochran noted that the trial demonstrated “a highly significant difference in stability patterns between SLActive and SLA implants during the critical early treatment period between weeks 2 and 4”. The change in stability pattern from decreasing primary stability to increasing secondary stability (break point) of the SLActive implant was twice as fast (2 weeks vs. 4 weeks; $p < 0.0001$ for mandibular implants) relative to SLA, which is consistent with preclinical results. The findings prove in patients that SLActive offers accelerated healing and secondary implant stability in the early healing period of 2-4 weeks. Prof. Cochran concluded that “SLActive may therefore offer increased predictability”.

Immediate and early loading working well; high patient satisfaction

Preliminary results from a multicenter study conducted in 19 centers around the world were discussed at the AO (Academy of Osseointegration) Meeting. In the study, which focuses on the challenging indications of immediate or early loading with SLActive, patients were randomized to receive the provisional tooth restoration either on the day of implant placement (immediate) or 4 weeks later (early). To date, the immediate and early loading protocols show equivalent survival rates (98% and 97% for immediate and early loading, respectively), suggesting that SLActive achieves secondary implant stability sooner during the critical loading period between weeks 2 and 4, consistent with conclusions from preclinical studies.¹⁴

Early loading, three weeks after placement in patients

A clinical study is also being conducted by the Universities of Bern and Florida to investigate the effect of early loading (21/22 days) after placement of SLActive implants in 60 patients. The preliminary results suggest that aggressive early loading protocols and soft tissue healing are predictable after three weeks.

SLActive broadly available on multiple Straumann implant types

SLActive has now become available on a broad range of Straumann implant types in Europe, North America and initial Asian markets and has been very well received.

Further information

More details about SLActive are published in *STARGET*, Straumann's customer magazine. Further information is also available at www.straumann.com/slactive.

Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland.
Phone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01
E-Mail: corporate.communication@straumann.com
Homepage: www.straumann.com

Contact:

Straumann Corporate Communication
+41 (0)61 965 13 21

References

- 1 Beagle J. Immediate and early loading clinical case reports with SLActive from the USA. Presentation at the 14th Annual Scientific Meeting of the European Association for Osseointegration, September 22-24, 2005, Munich, Germany.
- 2 De Wild M. Superhydrophilic SLActive implants. Straumann publication 151.527/d and 152.527/e.
- 3 Rupp F, Scheideler L, Olshanka N, de Wild M, Wieland M, Geis-Gerstorfer J. Enhancing surface free energy and hydrophilicity through chemical modification of microstructured titanium implant surfaces. *J Biomed Mater Res A* 2006;76(2):323-334.
- 4 Scheideler L, Rupp F, Wieland M, Geis-Gerstorfer J. Storage conditions of titanium implants influence molecular and cellular interactions. Poster #870, 83rd General Session and Exhibition of the International Association for Dental Research (IADR), March 9-12, 2005, Baltimore, MD, USA.
- 5 Seibl R, de Wild M, Lundberg E. *In vitro* protein adsorption tests on SLActive. TARGET 02.2005.
- 6 Buser D, Broggini N, Wieland M, Schenk RK, Denzer A, Cochran D, Hoffmann B, Lussi A, Steinemann SG. Enhanced bone apposition to a chemically modified SLA titanium surface. *J Dent Res* 2004;83(7):529-533.
- 7 Ferguson S, Broggini N, Wieland M, de Wild M, Rupp F, Geis-Gerstorfer J, Cochran D, Buser D. Biomechanical evaluation of the interfacial strength of a chemically modified SLA titanium surface. *J Biomed Mater Res A* (*accepted*).
- 8 Zhao G, Schwartz Z, Wieland M, Rupp F, Geis-Gerstorfer J, Cochran D, Boyan B. High surface energy of SLActive implants enhances cell response to titanium substrate microstructure. *J Biomed Mater Res A* 2005;74(1):49-58.
- 9 Rausch-Fan X, Zhe Q, Wieland M, Matejka M, Schedle A. The influence of hydrophilic versus hydrophobic Ti specimens with different topographical and roughness levels on contact guidance and cellular proliferation evaluated with time-lapse photography. (*In preparation*).
- 10 Schwarz F, Herten M, Sager M, Wieland M, Dard M, Becker J. Histological and immunohistochemical analysis of very early peri-implant tissue reactions to chemically modified and conventional SLA titanium implants: A pilot study in dogs. *Clin Oral Implants Res* (*accepted*).
- 11 Raghavendra S, Wood MC, Taylor TD. Early wound healing adjacent to endosseous dental implants: A review of the literature. *Int J Oral Maxillofac Implants* 2005;20(3):425-431.
- 12 Schwarz F, Herten M, Sager M, Wieland M, Dard M, Becker J. Bone regeneration in dehiscence-type defects at chemically modified (SLActive) and conventional SLA titanium implants: a pilot study in dogs. *J Clin Periodontol* 2007; 34: 78-86.
- 13 Schwarz F, Herten M, Sager M, Wieland M, Dard M, Becker J. histological and immunohistochemical analysis of initial and early subepithelial connective tissue attachment at chemically modified and conventional SLA titanium implants. A pilot study in dogs. *Clin Oral Investig* (*accepted*).
- 14 Norikin FJ, Ganeles J, Sekler J, Zfaz S. Predictable treatment success of SLActive implants in a multi-center RCT in aggressive protocols. Abstract #CI-03, 22nd Annual Meeting of the Academy of Osseointegration (AO), March 8-10, 2007, San Antonio, TX, USA.